Dr. Gottardis holds a Bachelor of Science degree in Biology from Columbia University and a PhD in Human Oncology from the University of Wisconsin-Madison. About NKGen Statements contained in this press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "could", "continue", "expect", "estimat ...

Dr. Song's presentation explored the potential benefits of eliminating pre-treatment lymphodepletion in patients undergoing SNK02 therapy, aiming to safeguard immune function and aid in recovery. Avoiding lymphodepletion before administering cancer treatment can provide many benefits including reduced toxicity, preservation of immune function and potentially enhancing treatment efficacy. The presentation also included a discussion on the results from the Company's Phase 1 SNK02 clinical study in solid tumor ...

Core Insights - The presentation by Dr. Song highlighted the potential benefits of eliminating pre-treatment lymphodepletion in patients undergoing SNK02 therapy, which may help preserve immune function and enhance recovery [1][5] - The Phase 1 clinical trial results indicated that SNK02 was well-tolerated as a monotherapy and showed clinical activity against heavily pretreated solid tumors without the need for lymphodepletion [2][6] Company Overview - NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on developing and commercializing innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics [5][9] - The company is headquartered in Santa Ana, California, and is dedicated to advancing NK cell therapies for a broad range of cancers [9] Clinical Trial Details - The Phase 1 clinical trial involved administering SNK02 intravenously on a weekly basis for a total of 8 weeks, starting with a dose of 6 x 10^9 SNK02 cells [6] - The trial enrolled 6 patients with advanced refractory solid tumors, with a median age of 64 years and an average of 4 prior lines of therapy [2] - Among the patients who completed 8 cycles of SNK02, 100% demonstrated stable disease, indicating that the tumor growth was halted [2] Safety and Efficacy - Adverse events related to the investigational product were reported, with 17 Grade 1, 3 Grade 2, and 1 Grade 3 adverse events observed, indicating a generally favorable safety profile [2][6] - The development of auto-antibodies was noted around Cycle 5, but there was no correlation with adverse events or tumor response [2] Future Directions - The company plans to further explore the efficacy of SNK02 in combination with immune checkpoint inhibitors and monoclonal antibodies for treating solid tumors [2][5]

SANTA ANA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details on their cryopreserved allogeneic NK cell therapy platform as well as updated Phase 1 data on its use in ...

Presentation Details: SANTA ANA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details on their cryopreserved allogeneic NK cell therapy platform as well as updated Phas ...

SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall synergy in future combination regimens with immune checkpoint inhibitors. In this Phase 1 trial, the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02. SNK02 was well tolerated as a monotherapy and appears to have some clinical activity agai ...

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40427NKGN NKGen Biotech, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...

Company Update - NKGen Biotech has received approval from its Safety Review Committee to commence its Phase 2 clinical study of SNK01, a drug aimed at treating moderate Alzheimer's disease [1][2] - The Phase 1 clinical trial results were positive, showing improved or maintained cognitive abilities after four doses, with no adverse effects reported [2] Clinical Trial Details - The Phase 2 trial will involve a larger patient group, with 20 patients receiving 20 doses of SNK01 and 10 patients receiving 10 placebo doses [2] - The CEO of NKGen Biotech expressed optimism about the clinical progress and the potential for significant clinical and biomarker data from the upcoming trial [3] Stock Performance - Following the announcement, NKGN stock experienced significant trading activity, with over 26 million shares traded, surpassing its average daily volume of 3.7 million shares [3] - As of Monday morning, NKGN stock price increased by 54% [4]

SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events. Company advances SNK01 into Phase 2 in moderate Alzheimer's disease; first patient enrolled in Phase 2 expected in Q2 2024. SANTA ANA, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercializa ...

SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events. Company advances SNK01 into Phase 2 in moderate Alzheimer's disease; first patient enrolled in Phase 2 expected in Q2 2024. SANTA ANA, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercializ ...